{"protocolSection":{"identificationModule":{"nctId":"NCT03529149","orgStudyIdInfo":{"id":"[2018]007"},"organization":{"fullName":"Xuanwu Hospital, Beijing","class":"OTHER"},"briefTitle":"TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT","officialTitle":"TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT"},"statusModule":{"statusVerifiedDate":"2018-04","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-04-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-06-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2019-06-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-04-22","studyFirstSubmitQcDate":"2018-05-06","studyFirstPostDateStruct":{"date":"2018-05-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-05-06","lastUpdatePostDateStruct":{"date":"2018-05-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xuanwu Hospital, Beijing","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":true,"isUsExport":true},"descriptionModule":{"briefSummary":"Investigators hypothesized that the precise regulation of blood pressure based on the changes of cerebral blood flow parameters under TCD monitoring can better improve the state of cerebral blood flow, reduce the risk of early neurological deterioration and improve the prognosis of the patients."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Accurate blood pressure control","type":"EXPERIMENTAL","description":"Implementing accurate blood pressure management under TCD monitoring","interventionNames":["Combination Product: Urapidil Hydrochloride Injection"]},{"label":"Guideline blood pressure control","type":"ACTIVE_COMPARATOR","description":"Control blood pressure according to guidelines","interventionNames":["Combination Product: Urapidil Hydrochloride Injection"]}],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Urapidil Hydrochloride Injection","description":"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\\>37cm/s of （middle cerebral artery)MCA, PI \\< 1.34cm/s, aMFV\\>40cm/s of (basilar artery)BA, PI \\< 0.8cm/s.\n\nTCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure.","armGroupLabels":["Accurate blood pressure control","Guideline blood pressure control"],"otherNames":["Diltiazem Hydrochloride for Injection"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"early neurological deterioration","description":"the incidence of 72 hours in National Institute of Health stroke scale increased more than 4 points or National Institute of Health stroke scale Ia score more than 1 points","timeFrame":"72 hours"}],"secondaryOutcomes":[{"measure":"prognosis of nerve function","description":"prognosis of nerve function use Modified Rankin Scale,0\\~3 is good prognosis and 4\\~6 is poor prognosis.","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years of age or older;\n* accept EVT treatment within 6 hours of symptoms onset;\n* In selected patients with AIS within 6 to 16 hours of last known normal who have LVO in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria..\n* In selected patients with AIS within 6 to 24 hours of last known normal who have LVO in the anterior circulation and meet other DAWN eligibility criteria.\n\nExclusion Criteria:\n\n* Pre - onset mRS\\>2;\n* severe dementia;\n* threatening life diseases (such as malignant tumor, etc.);\n* non acute ischemic cerebrovascular disease patients undergoing selective intravascular treatment;\n* related sound window closure can not be monitoring with TCD.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Xuanwu Hospital","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100053","country":"China","contacts":[{"name":"Su Yingying","role":"CONTACT","phone":"15901361953","email":"tangsuyingying@sina.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Acute Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000004110","term":"Diltiazem"},{"id":"C000015568","term":"Urapidil"}],"ancestors":[{"id":"D000000959","term":"Antihypertensive Agents"},{"id":"D000002121","term":"Calcium Channel Blockers"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000077264","term":"Calcium-Regulating Hormones and Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000017366","term":"Serotonin Receptor Agonists"},{"id":"D000018490","term":"Serotonin Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000058668","term":"Adrenergic alpha-1 Receptor Antagonists"},{"id":"D000000317","term":"Adrenergic alpha-Antagonists"},{"id":"D000018674","term":"Adrenergic Antagonists"},{"id":"D000018663","term":"Adrenergic Agents"}],"browseLeaves":[{"id":"M4544","name":"Benzocaine","relevance":"LOW"},{"id":"M6984","name":"Diltiazem","asFound":"Comb","relevance":"HIGH"},{"id":"M230528","name":"Urapidil","asFound":"Fixator","relevance":"HIGH"},{"id":"M3967","name":"Antihypertensive Agents","relevance":"LOW"},{"id":"M5071","name":"Calcium","relevance":"LOW"},{"id":"M5088","name":"Calcium, Dietary","relevance":"LOW"},{"id":"M5074","name":"Calcium Channel Blockers","relevance":"LOW"},{"id":"M9479","name":"Hormones","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"},{"id":"M15202","name":"Serotonin","relevance":"LOW"},{"id":"M19338","name":"Serotonin Receptor Agonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M20436","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M28884","name":"Adrenergic alpha-1 Receptor Antagonists","relevance":"LOW"},{"id":"M3359","name":"Adrenergic alpha-Antagonists","relevance":"LOW"},{"id":"M20445","name":"Adrenergic Antagonists","relevance":"LOW"},{"id":"T433","name":"Tannic Acid","relevance":"LOW"}],"browseBranches":[{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnAg","name":"Antihypertensive Agents"},{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"BDCA","name":"Bone Density Conservation Agents"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}